scholarly journals Clinical outcomes in post-epikeratophakic eyes after removal of epikeratoplasty lenticule

2021 ◽  
Vol 21 (1) ◽  
Author(s):  
Young-ho Jung ◽  
Mee Kum Kim
Keyword(s):  
Epithelial Cell ◽  
Clinical Characteristics ◽  
Case Series ◽  
Average Difference ◽  
Retrospective Case ◽  
Refractive Power ◽  
Case Series Study ◽  
Aphakic Eyes ◽  
The Mean ◽  
Series Study

Abstract Background Assessment of the optical outcome and adverse events in post-epikeratopathic eyes after removal of the epikeratoplasty lenticule (EKPL). Methods This was a retrospective case-series study of patients who underwent EKPL removal between 2002 and 2020. Ten eyes were included in the analysis. We compared the clinical characteristics of the patients before surgery, 6 months after surgery, before lenticular removal, and after removal, and reported optical or ocular surface complications. Results We removed EKPL due to the lenticular opacity in five eyes (50%), intraocular lens (IOL) insertion (n = 4, 40%) after cataract surgery (n = 3) or in aphakic eyes (n = 1), and lenticule-induced irregular astigmatism in one eye (10%). After EKPL removal, the mean refractive power of the cornea (Km) revealed a tendency to increase. Out of nine cases, six cases showed corneal steepening and three cases revealed corneal flattening. When the keratometric readings of pre-epikeratoplasty and post-lenticular removal were compared within the same case, the average difference was 5.1 D ± 4.0 (n = 8). Complications were observed in 3 of 10 cases (excessive corneal flatness, ectatic change, and abnormal epithelial cell ingrowth) after removal. Conclusions The surgeon should expect the corneal refractive power to steepen or flatten in some cases with abnormal astigmatism and irregularity. Epikeratophakic eyes may exhibit serious ectatic changes, and abnormal epithelial cell ingrowth after removal of epikeratophakic lenticules.

scholarly journals Subconjunctival injections of triamcinolone acetonide to treat uveitic macular edema

2019 ◽  
Author(s):  
Yi Qu ◽  
Xinshu Liu ◽  
Anyi Liang ◽  
Chan Zhao ◽  
Fei Gao ◽  
...  
Keyword(s):  
Macular Edema ◽  
Triamcinolone Acetonide ◽  
Case Series ◽  
Subconjunctival Injection ◽  
Retrospective Case ◽  
Case Series Study ◽  
Uveitic Macular Edema ◽  
The Mean ◽  
Series Study

Abstract Background: To evaluate the efficacy and safety of subconjunctival triamcinolone acetonide (TA) injections for treating uveitic macular edema (UME). Methods: This retrospective case series study included patients with UME who received subconjunctival TA injections with a minimum follow-up period of 6 months. The main outcome was central macular thickness. The secondary outcomes included the best corrected visual acuity, recurrence rate and intraocular pressure. Results: In total, 68 patients (83 eyes) were enrolled in this study. The mean CMT decreased from 456.9 ± 171.1 μm at baseline to 324 ± 175.9 μm, 305.6 μm ± 147.7 μm, 331.8 ± 154.3 μm and 281.1 ± 147.6 μm at 1, 2, 3 and 6 months postinjection, respectively (all P < 0.01). A total of 21/83 eyes exhibited elevated IOPs, which was controlled with topical IOP-lowering agents in 14 eyes, whereas 7 eyes got subconjunctival TA deposit surgically removed. Conclusion: subconjunctival TA injections appear to be safe and effective for UME.Key Words: Triamcinolone acetonide; subconjunctival injection; uveitis; macular edema

scholarly journals Childhood strokes in China describing clinical characteristics, risk factors and performance indicators: a case-series study

2021 ◽  
pp. svn-2021-001062
Author(s):  
Yaxian Deng ◽  
Gaifen Liu ◽  
Guitao Zhang ◽  
Juanyu Xu ◽  
Chunmei Yao ◽  
...  
Keyword(s):  
Risk Factors ◽  
Clinical Characteristics ◽  
Age At Onset ◽  
Case Series ◽  
Haemorrhagic Stroke ◽  
Epidemiological Studies ◽  
Neurological Deficits ◽  
Retrospective Case ◽  
Case Series Study ◽  
Series Study

AimTo investigate clinical characteristics, risk factors (RFs), neurologic deficits and medical care provided in children who had a stroke in China.MethodsWe conducted a retrospective case-series study using the medical records of children aged 1 month to 18 years with arterial ischaemic stroke (AIS) or haemorrhagic stroke (HS) (with the entry codes I60, I61, I62, I63 (ICD-10)), who were admitted to different hospitals in Beijing, between January 2018 and December 2018. We obtained the following information from the charts: demographic characteristics, clinical presentations, RFs for paediatric stroke, laboratory examination, neuroimaging records and neurologic sequelae.ResultsWe identified 312 first admissions for stroke (172 AIS and 140 HS). The mean age at onset was 8.6±3.9 years for patients who had an AIS and 8 (5–13) years for patients who had an HS. There were more males than females in both groups (AIS: 59.88% vs 40.12%; HS: 52.14% vs 47.86%). A known aetiology was identified in 92.44% and 86.43% of patients who had an AIS and HS, respectively. The leading cause of AIS was cerebrovascular diseases including moyamoya (68.6%), while that for HS was arteriovenous malformation (51.43%). The most common initial clinical presentation was hemiplegia (86.05%) in patients who had an AIS and headache (67.86%) in patients who had an HS. The use of healthcare, including acute treatment (antithrombotic in 17.44%, anticoagulant in 5.23%) and secondary prevention (antithrombotic in 6.39%, anticoagulant in 1.16%), varied and was significantly lower among patients who had an AIS. The most common complications were epilepsy (22.09%) and pneumonia (4.65%) in patients who had an AIS and epilepsy (17.14%) and hydrocephalus (12.14%) in patients who had an HS. Neurological deficits occurred in 62.8% of patients who had an AIS and 72.86% of patients who had an HS.ConclusionCerebral arteriopathy was a major RF for both AIS and HS in children living in China. Large epidemiological studies are required to identify RFs to prevent stroke as well as appropriate interventions.

Electrophysiological effects and clinical utility of propafenone in children

2021 ◽  
pp. 1-5
Author(s):  
Manavotam Singh ◽  
Keore McKenzie ◽  
Mark L. Hudak ◽  
Anil K. Gehi ◽  
Sunita J. Ferns
Keyword(s):  
Case Series ◽  
Clinical Effectiveness ◽  
Retrospective Case ◽  
Cardiac Side Effects ◽  
Cardiac Depression ◽  
Case Series Study ◽  
Baseline Characteristics ◽  
Antiarrhythmic Medication ◽  
Electrophysiological Effects ◽  
Series Study

Abstract Aim: This retrospective case series study sought to describe the safety and clinical effectiveness of propafenone for the control of arrhythmias in children with and without CHD or cardiomyopathy. Methods: We reviewed baseline characteristics and subsequent outcomes in a group of 63 children treated with propafenone at 2 sites over a 15-year period Therapy was considered effective if no clinically apparent breakthrough episodes of arrhythmias were noted on the medication. Results: Sixty-three patients (29 males) were initiated on propafenone at a median age of 2.3 years. CHD or cardiomyopathy was noted in 21/63 (33%). There were no significant differences between demographics, clinical backgrounds, antiarrhythmic details, side effect profiles, and outcomes between children with normal hearts and children with CHD or cardiomyopathy. Cardiac depression at the initiation of propafenone was more common amongst children with CHD or cardiomyopathy compared to children with normal hearts. Systemic ventricular function was diminished in 15/63 patients (24%) prior to starting propafenone and improved in 8/15 (53%) of patients once better rhythm control was achieved. Other than one child in whom medication was stopped due to gastroesophageal reflux, no other child experienced significant systemic or cardiac side effects during treatment with propafenone. Propafenone achieved nearly equal success in controlling arrhythmias in both children with normal hearts and children with congenital heart disease or cardiomyopathy (90% versus 86%, p = 0.88). Conclusion: Propafenone is a safe and effective antiarrhythmic medication in children.

NEAR FATAL AMITRAZ: A NOT SO UNCOMMON POISONING

2021 ◽  
pp. 42-43
Author(s):  
Rohan J Desai ◽  
Prasad Ugargol
Keyword(s):  
Mechanical Ventilation ◽  
Respiratory Failure ◽  
Clinical Features ◽  
Case Series ◽  
Agricultural Product ◽  
Common Symptom ◽  
Retrospective Case ◽  
Case Series Study ◽  
Cns Depression ◽  
Series Study

Background: Amitraz is a pharmaceutical, veterinary, and agricultural product which is used worldwide to control ectoparasites in animals. Its widespread use has led to increased cases of poisoning in rural parts of India. Aim: To study the clinical features, complications, laboratory abnormalities and outcome of the patients with acute amitraz intoxication. Methodology: The study is a retrospective case series study conducted in HSK hospital between the period of Feb 2019 and May 2020. Results: A total of 11 patients were analysed and results revealed CNS depression and vomiting in 8 of those patients with 1 patient with respiratory failure requiring mechanical ventilation. Conclusion: Amitraz poisoning appears to be severe with CNS depression being the most common symptom. But most patients stabilise and recover quickly. Patients should be monitored for respiratory failure as it is a dreadful complication. Treatment is symptomatic as no antidote is available.

The clinical characteristics of melanoma with BRAF V600R mutation: a case series study

2020 ◽  
Vol 30 (1) ◽  
pp. 107-112 ◽  
Author(s):  
Karen A. Malkhasyan ◽  
Sydney L. Rooney ◽  
Anthony N. Snow ◽  
Brian L. Swick ◽  
Mohammed M. Milhem ◽  
...  
Keyword(s):  
Clinical Characteristics ◽  
Case Series ◽  
Case Series Study ◽  
Series Study
Sign in / Sign up

Export Citation Format

Share Document